Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju, Korea.
Genome and Company, Pangyo-ro 255, Bundang-gu, Seongnam, Korea.
Microbiome. 2022 Nov 4;10(1):188. doi: 10.1186/s40168-022-01374-0.
Comparisons of the gut microbiome of lean and obese humans have revealed that obesity is associated with the gut microbiome plus changes in numerous environmental factors, including high-fat diet (HFD). Here, we report that two species of Bifidobacterium are crucial to controlling metabolic parameters in the Korean population.
Based on gut microbial analysis from 99 Korean individuals, we observed the abundance of Bifidobacterium longum and Bifidobacterium bifidum was markedly reduced in individuals with increased visceral adipose tissue (VAT), body mass index (BMI), blood triglyceride (TG), and fatty liver. Bacterial transcriptomic analysis revealed that carbohydrate/nucleoside metabolic processes of Bifidobacterium longum and Bifidobacterium bifidum were associated with protecting against diet-induced obesity. Oral treatment of specific commercial Bifidobacterium longum and Bifidobacterium bifidum enhanced bile acid signaling contributing to potentiate oxidative phosphorylation (OXPHOS) in adipose tissues, leading to reduction of body weight gain and improvement in hepatic steatosis and glucose homeostasis. Bifidobacterium longum or Bifidobacterium bifidum manipulated intestinal sterol biosynthetic processes to protect against diet-induced obesity in germ-free mice.
Our findings support the notion that treatment of carbohydrate/nucleoside metabolic processes-enriched Bifidobacterium longum and Bifidobacterium bifidum would be a novel therapeutic strategy for reprograming the host metabolic homeostasis to protect against metabolic syndromes, including diet-induced obesity. Video Abstract.
比较瘦人和肥胖人肠道微生物组的研究表明,肥胖与肠道微生物组以及包括高脂肪饮食(HFD)在内的许多环境因素的变化有关。在这里,我们报告双歧杆菌的两个物种对控制韩国人群的代谢参数至关重要。
基于 99 名韩国个体的肠道微生物分析,我们观察到在内脏脂肪组织(VAT)、体重指数(BMI)、血液甘油三酯(TG)和脂肪肝增加的个体中,长双歧杆菌和双歧双歧杆菌的丰度明显降低。细菌转录组分析显示,长双歧杆菌和双歧双歧杆菌的碳水化合物/核苷代谢过程与预防饮食诱导的肥胖有关。特定商业长双歧杆菌和双歧双歧杆菌的口服治疗增强了胆汁酸信号,有助于促进脂肪组织的氧化磷酸化(OXPHOS),导致体重增加减少和肝脂肪变性和葡萄糖稳态改善。长双歧杆菌或双歧双歧杆菌操纵肠道固醇生物合成过程,以防止无特定病原体小鼠的饮食诱导肥胖。
我们的研究结果支持这样一种观点,即治疗富含碳水化合物/核苷代谢过程的长双歧杆菌和双歧双歧杆菌可能是一种新的治疗策略,用于重新编程宿主代谢稳态,以预防代谢综合征,包括饮食诱导的肥胖。视频摘要。